Product type drives method selection. Small molecules typically pair with HPLC testing, volatile compounds run on gas chromatography, and biologics need specialized, non-chromatographic platforms. Sponsors who match method to drug form early build a testing program that holds up through stability studies, technology transfer, and regulatory review.
The sections below walk through method selection by product type, followed by the validation requirements that apply once a platform is chosen.
Key Takeaways
- Drug Form Sets the Starting Platform: Chemical structure and product type determine which analytical method comes first.
- HPLC and UPLC Anchor Small Molecule Testing: Assay, impurities, and dissolution testing for oral solids and liquids typically start with liquid chromatography.
- Volatile Compounds Require Gas Chromatography: Residual solvents and other volatile impurities need GC or GC-MS rather than HPLC.
- Biologics Need Orthogonal, Non-Chromatographic Methods: Proteins, mAbs, and mRNA therapeutics rely on techniques built around structure and function, not retention time alone.
- Validation Requirements Apply Regardless of Platform: Every method, chromatographic or not, has to meet the same specificity, accuracy, and robustness standards.
Method Selection by Product Type at a Glance
Product Type | Primary Method(s) |
Small molecule oral solids and liquids | HPLC, UPLC |
Volatile compounds and residual solvents | GC, headspace GC-MS |
Biologics (mAbs, proteins, mRNA) | LC-MS/MS peptide mapping, capillary electrophoresis, ligand-binding assays |
Inhalation products (MDIs, DPIs, nebulizers) | HPLC plus particle size and dose uniformity testing |
Drug-device combination products | HPLC plus E&L testing (ISO 10993, USP <661>) |
Elemental impurities (any product type) | ICP-MS |
Small Molecules: Where HPLC Testing Anchors the Method Set
Oral solids, oral liquids, topical creams, and gels make up the largest share of small molecule drug products. HPLC testing services support most of the core analytical testing categories these products need:
- Assay and related substances: Reverse-phase HPLC quantifies the active ingredient alongside degradation products and process impurities.
- Dissolution testing: A release requirement for most oral solid dosage forms, pairing a dissolution apparatus with HPLC or UV detection to measure drug release over time.
- UPLC as a faster alternative: Smaller particle columns cut run times and improve resolution for complex impurity profiles, using the same specificity, linearity, and precision parameters as HPLC.
For sponsors managing tight development timelines, UPLC can shorten testing turnaround without changing the underlying validation approach.
When HPLC Testing Alone Falls Short
HPLC testing works because most small molecule APIs and their impurities are non-volatile and soluble in a mobile phase. That assumption breaks down for residual solvents, some volatile process impurities, and certain packaging-derived compounds, where a compound’s volatility, not its molecular weight or polarity, becomes the limiting factor in method selection.
Volatile Compounds and Residual Solvents: Gas Chromatography Takes Over
Residual solvents left over from synthesis or formulation fall under ICH Q3C, and testing for them typically uses headspace gas chromatography. The headspace technique samples the vapor above a solution rather than injecting the solution directly, which suits volatile analytes far better than liquid chromatography.
GC-MS extends this approach by adding mass spectrometric detection, which improves specificity when multiple volatile compounds coelute or when a method needs to confirm compound identity rather than rely on retention time alone. This platform also supports some raw material and container closure testing, where volatile extractables need to be identified alongside quantified.
Biologics: Specialized Platforms Replace Traditional Chromatography
Monoclonal antibodies, recombinant proteins, and mRNA therapeutics require a separate testing model from small molecules. These products call for methods built around higher-order structure, charge variants, and biological activity rather than a single chromatographic separation:
- Peptide mapping (LC-MS/MS): Confirms primary sequence and identifies post-translational modifications.
- Capillary electrophoresis: Resolves charge variants and size variants that liquid chromatography alone may not separate cleanly.
- Ligand-binding assays: ELISA-based methods quantify potency and detect host cell protein impurities carried over from manufacturing.
- mRNA-specific methods: Purity methods distinguish full-length transcript from truncated species; separate methods detect residual double-stranded RNA.
Many biologics programs still use liquid chromatography alongside these platforms, for size-exclusion or ion-exchange separations. The difference is scale: a biologics program combines several platforms together, where HPLC often covers most release testing on its own for small molecules.
Inhalation and Combination Products Add Their Own Testing Layer
Not every product fits cleanly into the small molecule, volatile compound, or biologic categories above. Two product types call for their own method mix on top of standard chemistry testing:
- Inhalation products (MDIs, DPIs, nebulizer solutions): Delivered dose uniformity, particle size distribution (typically by laser diffraction or cascade impaction), and leak testing sit alongside standard HPLC assay and impurity methods. These methods depend equally on formulation and device performance.
- Drug-device combination products: A prefilled syringe or auto-injector needs standard HPLC-based chemistry testing for the drug component, plus extractables and leachables testing on the device and packaging materials, evaluated against ISO 10993 and USP <661> series standards.
For sponsors managing either product type, method selection becomes a two-track exercise: one method set for the drug substance or product, and a separate set governed by device and packaging standards. Planning for both tracks early, rather than treating device-related testing as an afterthought, keeps a combination product on schedule through submission.
Elemental Impurities Cut Across Every Product Type
Elemental impurity testing applies uniformly across small molecules and biologics alike. ICH Q3D and USP <232>/<233> require elemental impurity assessment for drug products regardless of modality, and inductively coupled plasma mass spectrometry (ICP-MS) is the platform of choice for this testing across product types. A sponsor developing both a small molecule and a biologic program will likely need ICP-MS support for both, even where the rest of the method set diverges completely.
Method Validation Requirements Apply Regardless of Platform
Selecting the right platform is only the first step. Every method, whether it runs on HPLC, GC, or a ligand-binding assay, has to go through analytical development and validation in a cGMP environment before it supports release or stability testing. Method development and validation by HPLC follows the same core parameters as any other platform: specificity, linearity, accuracy, precision, and robustness.
What ICH Q2(R2) Requires From Every Method
The ICH Q2(R2) guideline, adopted by ICH’s regulatory members in November 2023, extended the validation framework to cover spectroscopic and spectrometric data alongside traditional chromatographic methods, and refined validation expectations for biologics. A method developed for a biologic needs to satisfy the same validation rigor as an HPLC assay for a small molecule tablet.
Method transfer follows the same logic: a validated method moving to a new lab or site has to demonstrate equivalent performance at the receiving site, regardless of platform.
Matching Method Selection to Development Stage
Early development work can often tolerate a simpler, non-validated method while a program screens formulations or confirms feasibility. As a product moves toward clinical trials and commercial manufacturing, methods need to become stability-indicating and fully validated, with platform choice locked in well before a regulatory submission depends on the results. Sponsors who identify the right platform early, based on drug form and intended use, avoid the cost and timeline risk of re-developing a method later in the program.
HPLC Testing and Method Selection: Common Questions
Does HPLC testing work for every drug product?
HPLC testing suits most small molecule oral solids and liquids, but volatile compounds and biologics typically need gas chromatography or specialized non-chromatographic platforms instead.
What is the difference between HPLC and UPLC?
UPLC uses smaller particle columns to shorten run times and improve resolution, while requiring the same core validation parameters as HPLC.
Why do biologics need different testing methods than small molecules?
Biologics require methods that assess higher-order structure, charge variants, and biological activity, capabilities that go beyond traditional liquid chromatography.
When is GC-MS used instead of HPLC?
GC-MS applies to volatile compounds such as residual solvents and certain packaging-derived impurities, where a liquid chromatography method would not retain or resolve the analyte.
What does method validation require regardless of platform?
Every method needs to demonstrate specificity, linearity, accuracy, precision, and robustness before it supports release or stability testing, per ICH Q2(R2).
Get the Right Method for Your Product
Method selection depends on drug form, development stage, and where the product is headed regulatory-wise. Request a quote from BA Sciences to discuss method development and validation for your specific product.
Read More:
What Is Analytical Development in Pharmaceuticals?
You Should Own Your Analytical Methods: What It Means and Why It Matters
What Is Method Transfer in Pharmaceuticals?